Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Natco has received orphan drug designation from the US Food and Drug Administration (FDA) for its anti-cancer drug NRC-AN-019 for three indications - glioma, pancreatic cancer and chronic myelogenous leukaemia.
Subscribe to our email newsletter
The India-based company is close to completing the Phase I clinical trial of NRC-AN-019 in India, and is planning to conduct further clinical trials in the US and other countries.
Orphan drug designation is granted by the FDA to those drugs that treat rare diseases affecting less than 200,000 patients in the US.
FDA grants special incentives to the companies involved in the development of these drugs, such as a seven year marketing exclusivity, specific tax credits and waiver of prescription drug user fees.